Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, No.1 Dongjiaominxiang, Dongcheng District, Beijing, China.
Department of ophthalmology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
BMC Ophthalmol. 2024 Aug 21;24(1):360. doi: 10.1186/s12886-024-03641-0.
To retrospectively investigate clinical characterization and the long-term postoperative outcomes of retinoblastoma (RB) patients receiving enucleation with primary orbital implantation in early infancy (0-6 months old).
The clinical and follow-up data of 42 RB patients receiving enucleation with primary orbital implantation in early infancy at Beijing Tongren Hospital from December 2009 to January 2020 were analysed. The average follow-up time was 83 months. The patient group included 24 males and 18 females, 30 unilateral and 12 bilateral cases. A total of 44 eyes with 10 in stage D and 34 in stage E underwent 40 unilateral and 2 bilateral surgeries. 17 RB eyes received hydrogel and 27 RB eyes received hydroxyapatite implants. This study was performed by following the guideline of STROBE.
Enucleation combined with primary orbital implantation promoted survival and was safe with few and minor complications such as increased secretion, upper eyelid ptosis, and sunken eye sockets which were not affected by stages, lateralities, or implant materials. 55-80% RB patients exhibited satisfactory appearance and obvious or moderate motility of orbital implants according to the evaluation by doctors and family members. Family members were likely more optimistic about the appearance and more pessimistic about motility of the orbital implantation than doctors did.The quality of life was high as indicated by PedsQL3.0 or PedsQL4.0 scores ( ≧ 90 for > 75% patients). It was not affected by the stages, laterality, and implant materials, nor affected by the appearance and motility of the implants.
The outcomes of the combination of enucleation and primary orbital implantation for pertinent RB patients in early infancy are generally satisfactory with few and minor complications, high safety, appearance, and overall quality of life. Enucleation combined with primary orbital implantation in early infancy benefits pertinent RB patients in appearance, survival, and quality of life.
回顾性分析婴儿期(0-6 个月)行眼球摘除联合一期眶内植入治疗视网膜母细胞瘤(RB)患者的临床特征及长期术后转归。
收集 2009 年 12 月至 2020 年 1 月在北京同仁医院行婴儿期眼球摘除联合一期眶内植入术的 42 例 RB 患者的临床资料,随访时间平均 83 个月。男 24 例,女 18 例;单眼 30 例,双眼 12 例。肿瘤分期 D 期 10 眼,E 期 34 眼。行单侧眼球摘除 40 例,双侧眼球摘除 2 例。行义眼座植入 17 例,羟基磷灰石眼座植入 27 例。本研究遵循 STROBE 指南进行。
婴儿期行眼球摘除联合一期眶内植入术,术后患者生存良好,安全性高,术后并发症少且较轻,如分泌物增加、上睑下垂、眼球内陷等,且与分期、侧别、植入物材料无关。55%-80%的患者经医生和家属评估,眼部外观满意,眶内植入物运动明显或中度。家属对眶内植入物外观的满意度高于医生,对运动的满意度低于医生。PedsQL3.0 或 PedsQL4.0 评分(>75%的患者得分≧90)提示患儿生活质量高,与分期、侧别、植入物材料无关,也与植入物的外观和运动无关。
婴儿期行眼球摘除联合一期眶内植入术治疗 RB 疗效确切,并发症少,安全性高,患者外观及总体生活质量良好。婴儿期行眼球摘除联合一期眶内植入术有利于 RB 患者的外观、生存和生活质量。